<DOC>
	<DOCNO>NCT01470196</DOCNO>
	<brief_summary>Carfilzomib drug show anti-tumor activity inhibit proteasome within cell , responsible degrade break wide variety protein . Carfilzomib approve FDA . Rituximab dexamethasone often use treat Waldenstrom 's Macroglobulinemia ( WM ) , alone combination drug . Combinations rituximab , dexamethasone proteasome inhibitor , like carfilzomib , show high level activity WM patient . In research study , investigator test safety efficacy Carfilzomib use along Rituximab Dexamethasone possible treatment Waldenstrom 's Macroglobulinemia .</brief_summary>
	<brief_title>Carfilzomib , Rituximab Dexamethasone Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>If take part research study , receive Carfilzomib dexamethasone infusion Days 1 , 2 , 8 , 9 Cycles 1-6 . You Rituximab infusion Days 2 9 . Each cycle last 21 day . After complete Cycle 6 eligible , 2 month break maintenance phase start . During break , study visit physical exam , blood test , bone marrow biopsy . If continue maintenance phase , receive Carfilzomib Dexamethasone Days 1 2 Rituximab Day 2 Cycles 1-8 . Each cycle continue last 21 day , take place every 2 month . Infusions last 2-6 hour . During cycle physical exam ask question general health specific question problem might medication may take . Blood test also do Cycle visit , complete questionnaire . Bone marrow CT scan repeat physician discretion appropriate order ensure response treatment .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis Waldenstrom 's Macroglobulinemia Symptomatic disease Measurable disease Life expectancy great 12 week Adequate organ marrow function CD20 positive base previous perform bone marrow immunohistochemistry flow cytometric analysis Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast More one prior therapy Previous therapy proteasome inhibitor rituximab Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier Currently receive treatment malignancy Major surgery within 21 day prior study entry Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior study entry Uncontrolled hypertension uncontrolled diabetes Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior study entry Known history allergy Captisol Receiving study agent Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition carfilzomib , rituximab , and/or dexamethasone Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant lactate HIVpositive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>WM</keyword>
	<keyword>untreated</keyword>
	<keyword>symptomatic</keyword>
</DOC>